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Abstract
Background: Innovation contests are a novel approach to elicit good ideas and innovative practices in various
areas of public health. There remains limited published literature on approaches to deliver hepatitis testing. The
purpose of this innovation contest was to identify examples of different hepatitis B and C approaches to support
countries in their scale-up of hepatitis testing and to supplement development of formal recommendations on
service delivery in the 2017 World Health Organization hepatitis B and C testing guidelines.
Methods: This contest involved four steps: 1) establishment of a multisectoral steering committee to coordinate a
call for contest entries; 2) dissemination of the call for entries through diverse media (Facebook, Twitter, YouTube,
email listservs, academic journals); 3) independent ranking of submissions by a panel of judges according to pre-
specified criteria (clarity of testing model, innovation, effectiveness, next steps) using a 1-10 scale; 4) recognition of
highly ranked entries through presentation at international conferences, commendation certificate, and inclusion as
a case study in the WHO 2017 testing guidelines.
Results: The innovation contest received 64 entries from 27 countries and took a total of 4 months to complete.
Sixteen entries were directly included in the WHO testing guidelines. The entries covered testing in different
populations, including primary care patients (n = 5), people who inject drugs (PWID) (n = 4), pregnant women
(n = 4), general populations (n = 4), high-risk groups (n = 3), relatives of people living with hepatitis B and C (n = 2),
migrants (n = 2), incarcerated individuals (n = 2), workers (n = 2), and emergency department patients (n = 2). A
variety of different testing delivery approaches were employed, including integrated HIV-hepatitis testing (n = 12);
integrated testing with harm reduction and addiction services (n = 9); use of electronic medical records to support
targeted testing (n = 8); decentralization (n = 8); and task shifting (n = 7).
Conclusion: The global innovation contest identified a range of local hepatitis testing approaches that can be used
to inform the development of testing strategies in different settings and populations. Further implementation and
evaluation of different testing approaches is needed.
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Background
Hepatitis B virus (HBV) and HCV infection are major
causes of chronic liver disease globally and together ac-
count for about for about 1.34 million deaths per year,
mainly from cirrhosis or hepatocellular carcinoma [1, 2].
The recent development of highly effective, well-
tolerated oral treatment regimens with high rates of cure
after 12 weeks of treatment has revolutionized the treat-
ment of chronic HCV infection [3]. Effective long-term
antiviral treatment with tenofovir or entecavir is also
available for people with chronic HBV infection [4, 5].
Despite the high burden of disease and treatment ad-
vances, the majority of people infected with HBV [6, 7]
and HCV [8–10] remain unaware of their infection. Esti-
mates from the 2017 Global Hepatitis Report indicated
that only 9% of persons living with HBV (22 million)
and 20% of persons living with HCV (14 million) had
been tested and were aware of their diagnosis [2]. There
are several potential reasons for insufficient hepatitis
testing, including limited facilities for hepatitis testing,
lack of national testing policies, costly diagnostic assays,
complicated diagnostic algorithms, and inadequate qual-
ity assurance systems. A further barrier has been the
lack of service delivery models for hepatitis testing in
different settings and populations.
There are many potential facility or community based
approaches to delivery hepatitis testing [11]. Facility-
based opportunities include primary care and outpatient
clinics such as specialist clinics (e.g., HIV, TB and STI
clinics), inpatient services, and private services. Commu-
nity based testing can be offered through outreach and
mobile programmes in schools and workplaces. Al-
though many of these approaches were developed to
expand HIV testing [12], some of these may also be rele-
vant to expand viral hepatitis testing. WHO has recently
developed evidence-based testing guidelines for hepatitis
B and C virus infection [13]. The evidence-base included
several systematic reviews but recommendations were
also based on consideration of overall benefits and
harms, cost-effectiveness, resource use, acceptability,
and programmatic feasibility using the GRADE criteria
[14]. However, in contrast to HIV care for which there is
an extensive literature on different options for HIV test-
ing through health facilities and in different populations,
there is limited published literature on programmatic
experience of hepatitis testing [11, 13]. To address the
limited published literature and evidence-base to sup-
port different service delivery approaches to hepatitis
testing in the World Health Organization Hepatitis Test-
ing Guidelines, we used an innovation contest to solicit
a range of approaches to hepatitis B and C testing.
Innovation contests allow communities to identify novel
approaches to implementing public health interventions,
often with the help of the internet and multisectoral
partnerships [15]. The goal of the contest was to enrich
the guidelines with real-world practices in different set-
tings and populations. Previous health-focused innovation
contests solicited public health concepts, images [16, 17],
and videos [18, 19] to promote public health campaigns in
support of HIV testing [16, 19], healthy sexual behavior
[16, 20, 21], healthy eating habits [22–24], regular sun-
screen use [25, 26] and smoking cessation [27–29].
Common themes of these contests are the issuing of
an open call for entries, engaging a range of individuals
and groups, evaluation of entries, and recognition of fi-
nalists [16, 30]. The purpose of this paper is to describe
the methodology of an innovation contest and key find-
ings from the range of submissions.
Methods
Innovation contests
The innovation contest was organized through a collab-
oration between SESH (Social Entrepreneurship for
Sexual Health) and the World Health Organization
Global Hepatitis Programme. SESH has organized a total
of 16 innovation contests [16, 18, 30]. The contest was
initiated on December 15th 2015 with the formation of a
steering committee and was completed on April 17th
2016 with the announcement of finalists and issuing of
commendation certificates at the 2016 European Associ-
ation for the Study of the Liver (EASL) conference. The
contest had several discrete steps: 1) establishment of a
multisectoral steering committee to plan the contest; 2)
dissemination of the call for entries through diverse
media; 3) independent evaluation and ranking of entries
by a panel of judges according to pre-specified criteria;
4) recognition of contestants through commendation
and case studies in the WHO testing guidelines.
Establishment of a multisectoral steering committee to
plan the contest
A multisectoral steering committee was established with
representation from key stakeholders and geographic
regions. These included WHO (HQ Global Hepatitis
Programme and regional office focal points in hepatitis),
public health experts, implementing partners, social
media and communications experts, and advocacy orga-
nisations. The steering committee guided the overall
development, evaluation, and promotion of the contest
coordinated through a series of teleconferences. An open
call was made January 15th 2016 that explained the pur-
pose of the contest and solicited short descriptions of
programmes to promote hepatitis B and C testing. En-
tries were to include a description of the testing model;
a description of how it is novel with regard to promoting
uptake of testing in either setting, population or educa-
tion; data to support evidence of effectiveness and im-
pact of programme, including linkage to care; and next
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steps for continuing the work and ensuring sustainability
(Additional file 1). Eligible entries were those that de-
scribed existing ongoing programmes. The announce-
ment was translated into the six UN languages (French,
Chinese, Arabic, Russian, Spanish, English) and included
a link to a one-minute video explaining the contest, its
purpose, and how people could contribute (Additional
file 1). The hashtag “HepTestContest” identified the
campaign on social media platforms. All contestants
were also asked to complete a brief online survey that
asked when their testing programme started, what pro-
portion of the organization’s work was focused on hepa-
titis, the availability of direct acting antivirals in their
country, whether or not they also provided HIV testing,
and perceived barriers to testing.
Dissemination of the call for entries through diverse
media
In order to disseminate the call for entries widely, we
used several social media platforms (Twitter, Facebook,
and YouTube), as well as the email listservs and net-
works of collaborating organisations represented by the
steering committee. The call for entries was also in-
cluded in two academic journals, Journal of Virus Eradi-
cation and Hepatitis, Policy, and Medicine. The hashtag
“HepTestContest” was used to identify the campaign on
social media platforms. We used real-time social media
analytics from a video hosting site, innovation contest
webpage, Twitter hashtag activity, and submissions to
assess both total and regional engagement during the
6 weeks of soliciting entries.
Independent evaluation of entries by a panel of judges
according to pre-specified criteria
In addition to the Steering committee members,
additional persons were invited to participate in rating
the entries to increase representation from under-
represented regions and community-based organizations
(CBOs). A total of sixteen judges participated. Each
judge independently rated each of the four parts of the
abstract submission on a 1-10 scale: description of test-
ing model, innovation, effectiveness, and next steps for
sustainability, with 10 indicating a high and 1 a low
score. In addition, each judge gave an overall score of 1-
10. Judges who had a conflict of interest with a
programme recused themselves from reviewing that
entry. The three non-English entries were evaluated by
judges proficient in the language of the entry. Conflicts
were defined as collaborating, co-authoring, helping, re-
ceiving or providing monetary or other support, or any-
thing that could be perceived as a conflict of interest.
Judges entered their scores into an online scorecard de-
veloped in SurveyGizmo (Boulder, USA), a software
programme for creating online surveys. The software
facilitated data analysis and provided a common plat-
form to securely enter scores. An overall mean score
that averaged the means for each of the four subcompo-
nents (testing model, innovation, effectiveness, next
steps) was calculated.
Recognition of a subset of contestants through
commendation and inclusion in the WHO testing
guidelines
Entries that received an overall mean score of greater
than 6.0 (a threshold determined by the Steering
Committee, representing 15% of all submissions) on the
1-10 scale received a commendation of excellence from
EASL, on behalf of the Innovation Contest Steering
Committee, SESH and WHO. In addition, five of the fi-
nalists were invited to present their testing innovations
at the 2016 International Liver Congress (ILC)/EASL in
Barcelona, Spain. One finalist also presented at the
International AIDS Society conference (21 July 2016) in
Durban, South Arica and at the World Hepatitis Day (28
July 2016) in Mumbai, India. In addition, selected
submissions were included as case studies in the chapter
on service delivery within the WHO hepatitis testing
guidelines.
Results
Key characteristics of contest entries
We received 64 entries from 27 countries in all WHO
regions (Fig. 1). Among the 31 commended entries,
these included two from Africa (one from Egypt, one
from Nigeria), nine from Asia (three from India, two
from Australia, one from Malaysia, one from Indonesia,
one from Mongolia, one from China), six from Europe
(three from the UK, one from Georgia, one from the
Netherlands), and 14 from North America (all 14 from
the US). Among commended entries, 12/31 (39%) were
from non-government organizations, 10/31 (33%) were
from hospitals, 6/31 (19%) were from research organiza-
tions, and 4/31 (13%) were from governmental organiza-
tions. Nearly all (61/64) entries were in English and we
received one entry in Portuguese, one in Russian, and
one in Chinese. Of the 64 entries, 21 (33%) tested for
hepatitis B and C, 25 (39%) for hepatitis C only, and 10
(16%) for hepatitis B only. A total of 10/64 (16%) only
tested for hepatitis B, 25/64 (39%) only tested for hepa-
titis C, and 21/64 (33%) tested for both. The median
number of persons tested through each entry was 1367
(range 90 – 240,188) among the 39 entries that reported
testing numbers. A majority (42/64, 66%) of entries were
from testing programmes initiated in the past 3 years
and most (45/64, 71%) programmes also provided HIV
testing.
The 64 entries demonstrated a broad range of testing
locations, populations, and service models (Table 1). In
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terms of testing locations, 18 programmes were based at
clinical facilities; 11 were at non-clinical sites; two tested
at courthouses or prisons; and one in the workplace.
Populations tested in different programmes included six
testing people who inject drugs (PWID); four in preg-
nant women; three among the general population; three
in high-risk groups; two among relatives of people living
with hepatitis B and C; two among migrants; two in in-
carcerated individuals. Eight used electronic medical re-
cords in primary care to flag higher-risk populations for
testing. Five used social media to promote uptake of
testing. In terms of service models, several programmes
employed well–established health system programming
practices to support testing scale-up, including delivery
of integrated testing (12 HIV-hepatitis, and 9 with harm
reduction or addiction services); task sharing (n = 8) and
decentralisation (n = 8); and use of task shifting of test-
ing activities to other cadres of health workers (n = 8).
Survey responses about organizations
Respondents to an additional survey showed that the
majority (42/64, 66%) of entries were from testing pro-
grammes initiated in the past 3 years. Many of these
(45/64, 71%) also provided HIV testing. The pro-
grammes highlighted a number of barriers to effective
testing and treatment in the brief survey, which were
common across countries, testing models, and types of
organization. The most frequent barriers were lack of
hepatitis awareness among the public and subpopula-
tions (25/64, 39%), lack of testing supplies (25/64, 39%),
insufficient funding (10/64, 16%), lack of knowledge
among healthcare providers and community outreach
workers (10/64, 16%), insufficient linkage (9/64, 14%),
lack of drug access (8/64, 13%), stigma (4/64, 6%), and
local or national laws on illicit drugs (3/64, 5%). A high
proportion of organizations highlighted the need for
additional support in terms of resources (50/64, 78%),
communications (48/64, 75%), and technical expertise
(35/64, 55%).
Quality of entries
In general, the quality of entries was high (Fig. 2), with an
overall mean score across all judges and based on the four
different component scores of 5.65. 31 (46%) of entries re-
ceived an overall mean of greater than 6.0, and received a
commendation certificate from EASL (Table 1). Sixteen
submissions were included as short case studies in the
chapter on service delivery model in the 2017 WHO hepa-
titis testing guidelines.
Social media metrics
Video and website analytics suggested moderate engage-
ment over the 6 weeks of the call for entries. By the end
of the call for entries on March 1st, the video announce-
ment had been viewed 453 times in 87 countries (this
was 116 times in 37 countries within 2 weeks of the
announcement). Website metrics showed that fewer
individuals had accessed the announcements in Sub-
Saharan African countries and in Latin America. For
example, the respective number of website views early in
the contest over 5 days (27-31 January) were: Africa (6),
Americas (58), Eastern Mediterranean (2), Europe (114),
South-East Asia (4), and Western Pacific (24). Access to
both video and website analytics helped us to subse-
quently target further announcements through regional
networks that reached those under-represented regions
leading to modest increases in views from those regions.
Targeting was achieved by the Steering Committee
Fig. 1 Map of countries with contributions to the hepatitis testing innovation contest
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Table 1 Commended entries from the global hepatitis testing innovation contest, 2016, organized by region (n = 31)
Continent Country Organization
(Organization Type)
HBV/HCV Population Tested Setting Key feature of
service delivery
Health system
programme practices
Africa Egypt Association of Liver
Patients Care (NGO)
and the Egyptian Liver
Hospital (Hospital)
HBV/HCV General population Community
(non-clinical)
SMS promotion
Community
empowerment
Social marketing,
decentralization
Africa Nigeria Federal Ministry of
Health (Government)
HBV/HCV General population Community
(non-clinical)
Social media SMS promotion, public-
private partnership, task
shifting
Asia India Community Network for
Empowerment (NGO)
HCV PWID, PLHIV,
outpatients
Community
(clinical and
non-clinical)
Community
empowerment
Decentralization, task
shifting, public-private
partnership
Asia Mongolia Flagstaff International
Relief Effort (NGO)
HBV/HCV Health care workers,
social workers, and
family history of
liver cancer
Primary care
clinics
Integration with
primary care
Decentralization,
integration with HBV
immunization
Asia India Institute of Liver and
Biliary Sciences (Research)
HBV/HCV First degree relatives
of HBV+ patients;
PWID
Health facility
clinics
Family-focused
test promotion
Integration with HBV
immunization, task
shifting
Asia India Medecins Sans Frontieres
(NGO)
HCV PLHIV Health facility
clinics
HIV-hepatitis
integration
Task shifting
Asia Indonesia Persaudaraan Korban
Napza Indonesia (NGO)
HCV PWID Urban sites Peer-based HIV-hepatitis
integration, addiction
service integration
Asia Australia St Vincent’s Hospital
Melbourne and Justice
Department, Victorian State
Government (Hospital)
HCV Prisoners on entry
or transfer
Prison Prison-based
telemedicine
Integration with
primary care and
addiction services
Asia Australia The Kirby Institute, UNSW
Australia (Research)
HCV PWID Community
(clinic and
non-clinical)
Social media Social marketing,
addiction service
integration
Asia Malaysia University of Malaya-Center
of Excellence for Research
in AIDS (Research)
HCV PWID Methadone
clinic
Methadone clinic-
based services
Harm reduction/
addiction service
integration, peer-based
Asia China Yunnan AIDS Initiative
(NGO)
HBV Pregnant women
and partners
Maternal and
child health
clinics
Prenatal service
integration
HIV-hepatitis integration
Europe UK Barts Health NHS Trust
(Hospital)
HBV/HCV Emergency
department patients
Emergency
department
Social media HIV-hepatitis
integration, public-
private partnership
Europe UK Chelsea and Westminster
Hospital (Hospital)
HBV/HCV Emergency department
patients (HIV-negative)
Emergency
department
EMR, simplified
pathway for
emergency
department
testing
HIV-hepatitis
integration,
Europe Portugal IN-Mouraria (NGO) HBV/HCV PWID Substance
abuse programs
Comprehensive
harm reduction
services for PWID
HIV-hepatitis
integration, addiction
service integration,
peer-based, task shifting
Europe UK James Cook University
Hospital (Hospital)
HBV/HCV General population Health facility
clinics
EMR HIV-hepatitis integration
Europe Georgia Georgian Harm Reduction
Network (NGO)
HCV PWID Outreach
mobile sites
Methadone-based
service delivery
for PWID
Decentralization, public-
private partnership, task
shifting
Europe Netherlands Public Health Service of
Amsterdam (Government)
HCV “At Risk” based on
questionnaire
Health facility
clinics
Web-based risk
stratification and
referral
Use of social media to
promote access
North America US Emory University/Grady
Health System: Grady Liver
Clinic (Research/Hospital)
HCV Birth year
(1945-1965)
Primary care
clinics
EMR Decentralization
North America US Hep Free Hawaii (NGO) HBV/HCV General population Pharmacies EMR Use of social media to
promote access,
decentralization
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contacting regional networks to promote the contest
within their specific region.
Costs
We examined the costs of the contest solely from the
perspective of the contest organisation, and not the costs
associated with implementation of the testing ap-
proaches. There was no specific funding to support the
conduct of the contest. All steering committee members
and organizers of the contest volunteered their time,
while ILC-EASL supported the cost of having finalists
travel to and attend the EASL conference. The Office of
the WHO in the Southeast Region supported the cost of
travel and registration at the World Hepatitis Day event
in India.
Discussion
This global innovation contest led by a multi-sectoral
steering committee attracted 64 entries describing differ-
ent approaches to hepatitis B and C testing in 27 coun-
tries. Overall, the contest was straightforward to
organize and implement over a four-month period. The
contest elicited high-quality submissions from multiple
institutions and community organizations across all geo-
graphic regions. There were several distinct positive out-
comes from this initiative. First, the inclusion of a range
of examples of different service delivery models for test-
ing in different populations and settings as case studies
in the 2017 WHO hepatitis testing guidelines will be of
practical value to countries and programmes as they
start hepatitis testing activities. Second, the contest
Table 1 Commended entries from the global hepatitis testing innovation contest, 2016, organized by region (n = 31) (Continued)
Continent Country Organization
(Organization Type)
HBV/HCV Population Tested Setting Key feature of
service delivery
Health system
programme practices
North America US Horizon Health Center
(Hospital)
HCV New hospital and
clinic patients/and
untested for HIV in
previous 12 months
Health facility
clinics
EMR HIV-hepatitis integration
North America US Imagine Hope (NGO) HCV PWID Methadone
clinics and
substance
abuse
programmes
Addiction service
integration
HIV-hepatitis
integration, public-
private partnership
North America US Kaiser Permanente
Mid-Atlantic States
(Hospital)
HCV General population
& birth year
Primary care
clinics
EMR HIV-hepatitis integration
North America US Memorial Hermann
Healthcare System
(Hospital)
HCV Birth cohort
(1945-1965)
Emergency
department
EMR HIV-hepatitis
integration, public-
private partnership
North America US National Nursing Centers
Consortium (NGO)
HCV Outpatients Primary care
clinics
EMR HIV-hepatitis
integration, task shifting
North America US Philadelphia Department
of Public Health
(Government)
HCV PWID, including
homeless and sex
workers
Syringe
exchange
programmes
Addiction service
integration
Task shifting, peer-
based
North America US Project IMPACT (NGO) HCV General population Courthouse
lobby and
other sites
Courthouse
integration
HIV-hepatitis
integration, harm
reduction.addiction
service integration
North America US St Joseph’s Medical
Center (Hospital)
HBV/HCV General population
and those with
risk factors
Health facility
clinics
EMR NA
North America US St. Lukes-CHI/Project
ECHO (Hospital)
HCV Birth cohort and
among those
receiving STD tests
Primary care
clinics
Telemedicine Decentralization
North America US C a Difference, Drexel
University (Research)
HCV Outpatients Primary care
clinics
Social media HIV-hepatitis
integration,
decentralization
North America US Virginia Department of
Health, Division of Disease
Prevention (Government)
HCV PWID Methadone
clinics,
substance
abuse
programmes
Addiction service
integration
Decentralization, task
shifting
North America US Asian Liver Center at
Stanford University
(Research)
HBV Employees Workplace Workplace Public-private
partnership
SMS short message system, HBV hepatitis B virus, HCV hepatitis C virus, PWID people who inject drugs, PLHIV people living with HIV, STD sexually
transmitted disease, EMR electronic medical records (for risk stratification and clinician reminders)
The Author(s) BMC Infectious Diseases 2017, 17(Suppl 1):701 Page 182 of 196
succeeded in engaging multiple organisations who may
be in a position to undertake more formal evaluation of
their testing models, as well as provide input on future
hepatitis testing and treatment policy. Third, the contest
also served as an opportunity for non-governmental or-
ganizations to raise their profile and obtain recognition
for their work.
The contest identified a range of hepatitis B and C
testing approaches that can be used in both community
settings and health facilities such as integrated HIV-
hepatitis testing; use of social media to promote uptake
of testing; workplace testing; testing camps; using emer-
gency departments to promote testing; use of electronic
medical record prompts to flag higher risk patients for
targeted testing. In addition, the contest identified in-
novative testing approaches to reach different popula-
tions, such as PWID, prisoners and other high-risk
groups, migrants and relatives of people living with
hepatitis B or C.
The highlighting of the effectiveness of integration of
hepatitis testing within other programmes (eg. HIV,
mental health services), use of electronic and other re-
minders to prompt testing, and use of community-based
lay providers to deliver testing is consistent with studies
showing their effectiveness from both HIV [31] and
hepatitis care [11]. In particular, the availability of an
existing laboratory and clinical infrastructure, trained
personnel and funding streams presents a key opportun-
ity to build hepatitis testing into existing HIV testing
programmes [32–35]. However, the development of inte-
grated HIV and hepatitis testing will require additional
training and resources [36].
The contest also identified a number of well recog-
nized barriers to hepatitis testing, in particular poor
awareness among the general public and limited access
to test kits [37–39]. This finding is consistent with other
reports from LMICs [37, 38]. Poor awareness of hepatitis
B and C is likely related to many factors, including
limited resources for campaigns [40], a relative lack of
celebrity ambassadors for hepatitis [41, 42], and the
asymptomatic nature of chronic viral hepatitis in many
cases [43]. These challenges are consistent with experi-
ence reported from other innovation contests focused
on promoting HIV testing [16, 19].
We identified several key features that may have
contributed to success of this contest. First, the estab-
lishment of a diverse steering committee (including indi-
viduals in academia, civil society, government, WHO,
medicine, and public health) helped disseminate the call
for entries and evaluate entries. Second, we offered in-
centives to participate that included presentation at
international conferences and potential inclusion within
the WHO guidelines which may have been important in
motivating participation. Although the profiles provided
were brief, several contest submissions have since pub-
lished more detailed descriptions of their programmes
and evidence of impact [44–49]. Third, real-time
tracking of social media analytics during the contest en-
hanced subsequent contest promotion towards under-
represented regions.
However, there were several limitations to the use of a
contest approach to identify innovative models. First,
this contest relied on the internet, especially social
media, to distribute the call for entries and submit an
entry. As a result, contest entries were not representative
of all regions, settings, testing models, and populations.
We received fewer submissions from Latin America and
Africa, and only three entries in non-English languages
despite announcing the call for submissions in six lan-
guages. This may be related to insufficient dissemination
through those regional networks, less internet access,
and fewer ongoing hepatitis testing programmes in those
settings. Other crowdsourcing contests have demon-
strated the additional value of in-person promotion [16].
Second, the evaluation of quality of submissions was
only based on a 300 word description, without further
opportunity to clarify or extend. Importantly, only just
over half of entries formally evaluated the impact of
their programme, and we further noted that several pro-
grammes expressed challenges in funding, indicating
Fig. 2 Histogram showing range of scores submitted to the global hepatitis innovation contest (n = 64)
The Author(s) BMC Infectious Diseases 2017, 17(Suppl 1):701 Page 183 of 196
uncertainty about the financial viability and sustainabil-
ity of some of these approaches.
Conclusions
In conclusion, our experience suggests that this contest
was a useful way of eliciting a wide range of program-
matic experience that can supplement and enrich formal
evidence reviews to inform guidelines and policy, and
maybe applicable to other areas. Case studies were in-
cluded in the 2017 WHO viral hepatitis testing guide-
lines, as they were in the 2015 WHO consolidated
guidelines on HIV testing [31]. The inclusion of good
practice examples may serve as a useful model for future
international guidelines. However, there remains a need
for more systematic evaluation of these different service
delivery approaches in different populations. Ultimately,
countries will need to identify the most appropriate mix
of facility and community based testing opportunities ac-
cording to local epidemiology, current testing coverage,
existing health-care and testing infrastructure and ser-
vices, and available financial and human resources.
Additional file
Additional file 1: HepTestContest Call for Entries. This provides the
logo, call for entries, and related information released to solicit entries.
(DOCX 38 kb)
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